click on circles to display study description...
atezolizumab alone (n=-9) vs. placebo (n=-9)
randomized controlled trial
Atezolizumab
Placebo
metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA)
double-blind
atezolizumab alone (n=103) vs. sunitinib (n=101)
randomized controlled trial
atezolizumab
atezolizumab 1,200mg fixed intravenous dose every three weeks
sunitinib
sunitinib 50mg/d orally for four weeks followed by two weeks of rest
3 bras : atezolizumab, atezolizumab and bevacizumab, sunitinib, patients randomized to atezolizumab monotherapy or sunitinib had the option to cross over and receive the atezolizumab bevacizumab combination in some regions
metastatic/advanced RCC (mRCC) - 1st line (L1)
patients had a Karnofsky performance score ≥ 70, . Patients were required to have adequate hematologic and end-organ function.
open-label
96 institution
P2/interim analysis planned but no treshhold, no stratistic plan found (no protocol)
Overall, data from IMmotion150 suggest (did not demonstrare PFS benefit) that atezolizumab plus bevacizumab may particularly enhance PFS benefit in patients with pre-existing antitumor immunity (as determined by a high Teff score and PD-L1 IC expression) compared with sunitinib
atezolizumab plus bevacizumab (n=101) vs. sunitinib (n=101)
randomized controlled trial
atezolizumab with bevacizumab
atezolizumab 1,200mg fixed intravenous dose bevacizumab 15mg/kg every three weeks
sunitinib
sunitinib 50mg/d orally for four weeks followed by two weeks of rest
3 bras : atezolizumab, atezolizumab and bevacizumab, sunitinibpatients randomized to atezolizumab monotherapy or sunitinib had the option to cross over and receive the atezolizumab bevacizumab combination in some regions
metastatic/advanced RCC (mRCC) - 1st line (L1)
patients had a Karnofsky performance score ≥ 70, . Patients were required to have adequate hematologic and end-organ function.
open-label
96 institution
P2/interim analysis planned but no treshhold, no stratistic plan found (no protocol)
Overall, data from IMmotion150 suggest (did not demonstrare PFS benefit) that atezolizumab plus bevacizumab may particularly enhance PFS benefit in patients with pre-existing antitumor immunity (as determined by a high Teff score and PD-L1 IC expression) compared with sunitinib
atezolizumab plus bevacizumab (n=454) vs. sunitinib (n=461)
randomized controlled trial
atezolizumab plus bevacizumab
atezolizumab 1200 mg intravenously then bevacizumab 15 mg/kg intravenous infusions once every 3 weeks.
Sunitinib
sunitinib 50 mg once daily orally for 4 weeks, followed by 2 weeks of rest
No prespecified crossover was planned per protocol. Patients could continue atezolizumab plus bevacizumab or sunitinib
metastatic/advanced RCC (mRCC) - 1st line (L1)
Patients were excluded if they had received previous systemic treatment or if they had untreated brain metastases.
open label
152 sites across 21 countries
P3 / two-sided test procedure with two interim analysis. AI 1 (12 months) repartition between coprmary endpoints (0.04 PFS and 0.01 OS) and then hierarchy with OS (PDL1>1%)
Atezolizumab plus bevacizumab did not significantly prolonged progression-free survival versus sunitinib in patients with metastatic renal cell carcinoma but showed a favourable safety profile.
atezolizumab plus cabozantinib (n=263) vs. cabozantinib (n=259)
randomized controlled trial
atezolizumab plus cabozantinib
atezolizumab (1200 mg intravenously every 3 weeks) plus cabozantinib (60 mg orally once daily)
cabozantinib alone
cabozantinib (60 mg orally once daily) cabozantinib (60 mg orally once daily)
metastatic/advanced RCC (mRCC) - 2nd line (L2)
open-label
135 study sites in 15 countries in Asia, Europe, North America, and South America
atezolizumab plus bevacizumab (n=276) vs. sunitinib (n=277)
randomized controlled trial
atezolizumab plus bevacizumab
atezolizumab 1200 mg intravenously then bevacizumab 15 mg/kg intravenous infusions once every 3 weeks.
Sunitinib
sunitinib 50 mg once daily orally for 4 weeks, followed by 2 weeks of rest
No prespecified crossover was planned per protocol. Patients could continue atezolizumab plus bevacizumab or sunitinib
mRCC - L1 - PDL1 negative
Patients were excluded if they had received previous systemic treatment or if they had untreated brain metastases.
open label
152 sites across 21 countries
P3 / two-sided test procedure with two interim analysis. AI 1 (12 months) repartition between coprmary endpoints (0.04 PFS and 0.01 OS) and then hierarchy with OS (PDL1>1%)
Atezolizumab plus bevacizumab did not significantly prolonged progression-free survival versus sunitinib in patients with metastatic renal cell carcinoma but showed a favourable safety profile. exploratory results for this arm
atezolizumab alone (n=54) vs. sunitinib (n=60)
randomized controlled trial
atezolizumab
atezolizumab 1,200mg fixed intravenous dose every three weeks
sunitinib
sunitinib 50mg/d orally for four weeks followed by two weeks of rest
3 bras : atezolizumab, atezolizumab and bevacizumab, sunitinibpatients randomized to atezolizumab monotherapy or sunitinib had the option to cross over and receive the atezolizumab bevacizumab combination in some regions
mRCC - L1 - PDL1 positive
patietns had a Karnofsky performance score ≥ 70, . Patients were required to have adequate hematologic and end-organ function.
open-label
96 institution
P2/interim analysis planned but no treshhold, no stratistic plan found (no protocol)
Overall, data from IMmotion150 suggest (did not demonstrare PFS benefit) that atezolizumab plus bevacizumab may particularly enhance PFS benefit in patients with pre-existing antitumor immunity (as determined by a high Teff score and PD-L1 IC expression) compared with sunitinib
atezolizumab plus bevacizumab (n=50) vs. sunitinib (n=60)
randomized controlled trial
atezolizumab with bevacizumab
atezolizumab 1,200mg fixed intravenous dose bevacizumab 15mg/kg every three weeks
sunitinib
sunitinib 50mg/d orally for four weeks followed by two weeks of rest
3 bras : atezolizumab, atezolizumab and bevacizumab, sunitinibpatients randomized to atezolizumab monotherapy or sunitinib had the option to cross over and receive the atezolizumab bevacizumab combination in some regions
mRCC - L1 - PDL1 positive
they had a Karnofsky performance score ≥ 70, . Patients were required to have adequate hematologic and end-organ function.
open-label
96 institution
P2/interim analysis planned but no treshhold, no stratistic plan found (no protocol)
Overall, data from IMmotion150 suggest (did not demonstrare PFS benefit) that atezolizumab plus bevacizumab may particularly enhance PFS benefit in patients with pre-existing antitumor immunity (as determined by a high Teff score and PD-L1 IC expression) compared with sunitinib
atezolizumab plus bevacizumab (n=178) vs. sunitinib (n=184)
randomized controlled trial
atezolizumab plus bevacizumab
atezolizumab 1200 mg intravenously then bevacizumab 15 mg/kg intravenous infusions once every 3 weeks.
Sunitinib
sunitinib 50 mg once daily orally for 4 weeks, followed by 2 weeks of rest
No prespecified crossover was planned per protocol. Patients could continue atezolizumab plus bevacizumab or sunitinib
mRCC - L1 - PDL1 positive
Patients were excluded if they had received previous systemic treatment or if they had untreated brain metastases.
open label
152 sites across 21 countries
P3 / two-sided test procedure with two interim analysis. AI 1 (12 months) repartition between coprmary endpoints (0.04 PFS and 0.01 OS) and then hierarchy with OS (PDL1>1%)
Atezolizumab plus bevacizumab did not significantly prolonged progression-free survival versus sunitinib in patients with metastatic renal cell carcinoma but showed a favourable safety profile. exploratory results for this arm
powered by vis.js Network